MAJOR VARIATION – STRAIN CLEARANCE (MaV-SC) OF HUMAN INFLUENZA VACCINES APPLICATION

Who May Avail : All Manufacturers, Distributors, Importers, Exporters, Wholesalers, and Traders of Human Influenza Vaccines

Fees to be Paid : **Major Variation – Strain Clearance (MaV-SC)**
PHP 20,000 + LRF

CHECKLIST OF REQUIREMENTS

(Submit all relevant sections of the ACTD/CTD. Sections which were deemed not relevant should be justified adequately in the Summary/Overview.)

Part I: Administrative Data and Product Information

Sec. A: Introduction
Sec. B: Table of Contents
Sec. C: Guidance on the Administrative Data and Product Information

1. Integrated Application Form (with proof of payment)
2. Certifications

For contract manufacturing:
a. License of pharmaceutical industries and contract manufacturer
b. Contract manufacturing agreement
c. GMP certificate of contract manufacturer

For manufacturing "under-license":
a. License of pharmaceutical industries
b. GMP certificate of the manufacturer
c. Copy of "under-license" agreement

For locally manufactured products:
a. Valid License to Operate (LTO) (Manufacturer/Packer/Repacker/Trader/Distributor/ Wholesaler)
b. Valid GMP certificate

For imported products:
a. Foreign GMP Clearance
b. License of pharmaceutical industries/importer/wholesaler (country specific)
c. Certificate of Pharmaceutical Product (CPP) issued by the competent authority in the country of origin according to the current WHO format
If the product is not marketed in the country of origin the following should be submitted:
c.1. CPP indicating that the product is for export only or Certificate of Export
c.2. Authenticated Certificate of Free Sale (CFS) or CPP where it is marketed
If the country of origin does not issue a CPP the following should be submitted:
c.3. Justification that the country of origin does not issue a CPP
c.4. Authenticated CFS or CPP where it is marketed

3. Labeling (new strains)
4. Product Information
    a. Package Insert
    b. Summary of Product Characteristics (Product Data Sheet)

Part II: Quality

Sec. A: Table of Contents
Sec. B: Quality Overall Summary (addendum to "previous" QOS)
Sec. C: Body of Data

Drug Substance (S)

S 2 Manufacture
- S 2.1. Manufacturer(s)
- S 2.2. Description of Manufacturing Process and Process Controls
- S 2.3. Control of Materials
    - Seed lots: history:
    - Passage level
    - Characterization of Haemagglutinin and Neuraminidase
    - Analytical protocols (including test results on seed lots)*
- S 2.4. Control of Critical Steps and Intermediates
- S 2.5. Process Validation and/or Evaluation
    - Monovalent bulks:
    - Manufacturing process strain specific changes
    - Validation of critical manufacturing steps (e.g. inactivation, splitting efficiency) (new strains)

S 3 Characterization
- S 3.1. Elucidation of Structure and Characteristics
- S 3.2. Impurities

S 4 Control of Drug Substance
- S 4.1. Specifications
- S 4.2. Analytical Procedures
- S 4.3. Validation of Analytical Procedures
    - Validation study reports and summaries of test method [e.g. validation of Single Radial Diffusion (SRD) test for the new strain(s)]
- S 4.4. Batch Analyses
    - Results of monovalent bulks: results (including test for neuraminidase): Each working seed lot from previously approved master seed lot where the procedure of working seed lot preparation is different from the approved procedure
- S 4.5. Justification of Specifications

S 7 Stability

(Stability tests on the active substances: results from monovalent bulks where they are used for more than one year)

Drug Product (P)

P 1 Description and Composition
P 2 Pharmaceutical Development

P 2.2. Components of the Drug Product
P 2.2.1. Active Ingredients
P 3 Manufacture
P 3.1. Batch Formula
P 5 Control of Finished Product
P 5.1. Specifications
P 5.2. Analytical Procedures
P 5.3. Validation of Analytical Procedures
P 5.4. Batch Analyses
P 5.5. Characterization of Impurities
P 8 Product Stability

Part IV: Clinical Document

Sec. A: Table of Contents
Sec. B: Clinical Overview

1. Product Development Rationale
2. Overview of Biopharmaceutics
3. Overview of Clinical Pharmacology
4. Overview of Efficacy
5. Overview of Safety
6. Benefits and Risks Conclusions

Sec. D: Tabular Listing of All Clinical Studies
Sec. E: Clinical Study Reports (if applicable)

Additional Requirements:

1. Representative Samples (with corresponding Certificate of Analysis) may be submitted at a later date, e.g., when the application has already been decked as indicated in the Document Tracking System.
2. Risk Management Plan
3. Periodic Safety Update Report (PSUR)/Periodic Benefit-Risk Evaluation Report (PBRER)
4. List of Countries where the product is already licensed and the date of approval
5. Information on the number system of the lots or batches
6. Summary Lot Protocol
7. Lot to Lot Consistency from three (3) consecutive batches
8. Copy of valid Certificate of Product Registration (CPR)
9. Notarized Letter of Request for Major Variation – Strain Clearance (refer to Appendix 2) indicating the affected product, as well as declaration that there is/are no other change/s except from the update on the annual strain. This shall be signed by the Head of Regulatory Office.
10. Adverse event following immunization report (summary of annual reports)

Additional Requirement:

- Data on the testing of the seed virus for extraneous agents using Polymerase Chain Reaction (PCR) (where applicable)

END